机器人对比开放胰十二指肠切除术治疗胰腺及壶腹周围肿瘤(PORTAL):多中心III期非劣效随机对照试验研究方案
PORTAL试验是在中国7个高容量中心开展的多中心、随机对照、患者盲法、平行组、III期非劣效试验,计划纳入244例因恶性、癌前或症状性良性胰腺及壶腹周围病变行择期胰十二指肠切除术的患者,主要结局为术后功能恢复时间(天),次要结局包括术后并发症、死亡率和围手术期费用,另设128例胰腺导管腺癌亚队列比较术后8周内辅助化疗比例。
要点
- PORTAL为多中心III期非劣效随机对照试验,计划纳入244例择期胰十二指肠切除术患者。
- 主要结局为术后功能恢复时间(天),次要结局包括并发症、死亡率和围手术期费用。
- 128例胰腺导管腺癌亚队列比较术后8周内辅助化疗比例及复发模式、无复发生存和总生存。
核心结论
- PORTAL试验旨在评估机器人胰十二指肠切除术对比开放胰十二指肠切除术在功能恢复方面的可行性和安全性,并在胰腺导管腺癌亚队列中探讨机器人手术是否增加术后辅助化疗的可及性。
研究设计与样本
- 多中心、随机对照、患者盲法、平行组、III期非劣效试验,在中国7个胰腺和机器人手术高容量中心开展,每个参与中心每年完成超过20例机器人胰十二指肠切除术和超过100例开放胰十二指肠切除术。
- 计划纳入并随机分配244例因恶性壶腹周围及胰腺病变,以及癌前和症状性良性壶腹周围及胰腺疾病而具有择期胰十二指肠切除术指征的患者。
- 另设128例胰腺导管腺癌亚队列进行比较。
关键数值与推荐
- 主要结局为术后功能恢复时间,以天为单位测量。
- 次要结局包括术后并发症和死亡率,以及围手术期费用。
- 胰腺导管腺癌亚队列将比较各臂术后8周内接受辅助化疗的患者百分比,次要结局包括疾病复发模式、无复发生存和总生存。
- 试验注册于ClinicalTrials.gov,注册号为NCT04400357,注册日期为2020年5月22日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatoduodenectomy is a complex and challenging procedure that requires meticulous tissue dissection and proficient suturing skills. Minimally invasive surgery with the utilization of robotic platforms has demonstrated advantages in perioperative patient outcomes in retrospective studies. The development of robotic pancreatoduodenectomy (RPD) in specific has progressed significantly, since first reported in 2003, and high-volume centers in pancreatic surgery are reporting large patient series with improved pain management and reduced length of stay. However, prospective studies to assess objectively the feasibility and safety of RPD compared to open pancreatoduodenectomy (OPD) are currently lacking. METHODS/DESIGN: The PORTAL trial is a multicenter randomized controlled, patient-blinded, parallel-group, phase III non-inferiority trial performed in seven high-volume centers for pancreatic and robotic surgery in China (> 20 RPD and > 100 OPD annually in each participating center). The trial is designed to enroll and randomly assign 244 patients with an indication for elective pancreatoduodenectomy for malignant periampullary and pancreatic lesions, as well as premalignant and symptomatic benign periampullary and pancreatic disease. The primary outcome is time to functional recovery postoperatively, measured in days. Secondary outcomes include postoperative morbidity and mortality, as well as perioperative costs. A sub-cohort of 128 patients with pancreatic adenocarcinoma (PDAC) will also be compared to assess the percentage of patients who undergo postoperative adjuvant chemotherapy within 8 weeks, in each arm. Secondary outcomes in this cohort will include patterns of disease recurrence, recurrence-free survival, and overall survival. DISCUSSION: The PORTAL trial is designed to assess the feasibility and safety of RPD compared to OPD, in terms of functional recovery as described previously. Additionally, this trial will explore whether RPD allows increased access to postoperative adjuvant chemotherapy, in a sub-cohort of patients with PDAC. TRIAL REGISTRATION: ClinicalTrials.gov NCT04400357 . Registered on May 22, 2020.
引用
- Jin J, Shi Y, Chen M, et al. Robotic versus Open Pancreatoduodenectomy for Pancreatic and Periampullary Tumors (PORTAL): a study protocol for a multicenter phase III non-inferiority randomized controlled trial. Trials. 2021. PMID: 34961558. doi:10.1186/s13063-021-05939-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。